Rigel Pharmaceuticals Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
FY EPS (est.)
$2.92next fiscal year
Monitoring Framework
Key Performance Indicators
Net Product Sales Quarterly54.9MTarget: 255000000 to 265000000
Total Revenues Quarterly58.8MTarget: 275000000 to 290000000
Cash, Cash Equivalents, and Short-term Investments Quarterly146.7M
Watch Items
- R289 Phase 1b study in lower-risk MDSTrigger: Dose expansion enrollment completion and recommended Phase 2 dose selectionAction: Evaluate top-line dose-expansion data expected by the end of 2026 to determine initiation of Phase 2 trials.
- Veppanu (vepdegestrant) commercial launchTrigger: Hart-Scott-Rodino Antitrust Improvements Act clearance and transition milestonesAction: Monitor transition milestones and commercial launch execution in the US following the exclusive global licensing agreement.
Research as of 19 Jun 2026